BACKGROUND: Prolonged treatment with antiprogestin results in shrinkage of benign uterine leiomyomata. Leiomyomata and uterine leiomyosarcomas share some common features, and they both often express progesterone receptors. Thus, treatment of uterine leiomyosarcomas with antiprogestins has been suggested. CASES: The antiprogestin mifepristone was administered (50-200 mg/d) to three patients with recurrent uterine leiomyosarcomas. A dramatic response lasting more than 3 years was observed in a case of recurrent low-grade (G1) progesterone receptor-positive leiomyosarcomas. In two other patients, with G3 leiomyosarcomas, the disease progressed despite several months of mifepristone therapy. CONCLUSION: We speculate that mifepristone has a role in the management of some cases of recurrent uterine leiomyosarcomas.
BACKGROUND: Prolonged treatment with antiprogestin results in shrinkage of benign uterine leiomyomata. Leiomyomata and uterine leiomyosarcomas share some common features, and they both often express progesterone receptors. Thus, treatment of uterine leiomyosarcomas with antiprogestins has been suggested. CASES: The antiprogestin mifepristone was administered (50-200 mg/d) to three patients with recurrent uterine leiomyosarcomas. A dramatic response lasting more than 3 years was observed in a case of recurrent low-grade (G1) progesterone receptor-positive leiomyosarcomas. In two other patients, with G3 leiomyosarcomas, the disease progressed despite several months of mifepristone therapy. CONCLUSION: We speculate that mifepristone has a role in the management of some cases of recurrent uterine leiomyosarcomas.
Authors: Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley Journal: Gynecol Oncol Date: 2009-11-24 Impact factor: 5.482
Authors: James H Lewis; Paul H Cottu; Martin Lehr; Evan Dick; Todd Shearer; William Rencher; Alice S Bexon; Mario Campone; Andrea Varga; Antoine Italiano Journal: Drug Saf Date: 2020-10 Impact factor: 5.606
Authors: Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria Journal: Mol Cancer Date: 2008-10-23 Impact factor: 27.401
Authors: Paul H Cottu; Jacques Bonneterre; Andrea Varga; Mario Campone; Alexandra Leary; Anne Floquet; Dominique Berton-Rigaud; Marie-Paule Sablin; Anne Lesoin; Keyvan Rezai; François M Lokiec; Catherine Lhomme; Jacques Bosq; Alice S Bexon; Erard M Gilles; Stefan Proniuk; Veronique Dieras; David M Jackson; Alexander Zukiwski; Antoine Italiano Journal: PLoS One Date: 2018-10-10 Impact factor: 3.240